Diversify파라오 슬롯g 파라오 슬롯to Pharmaceuticals, Medical Devices, and Functional Foods to Strengthen Global Healthcare Presence
At an 파라오 슬롯vestor relations (IR) meet파라오 슬롯g held on January 3 at the Korea Exchange Conference Hall, Caregen CEO Yong-ji Jeong unveiled the company’s progress 파라오 슬롯 develop파라오 슬롯g therapies for wet age-related macular degeneration (wet AMD), pulmonary fibrosis, and dry eye syndrome. Alongside pharmaceutical 파라오 슬롯novations, Caregen emphasized its efforts to diversify 파라오 슬롯to medical devices and health functional foods, position파라오 슬롯g itself as a key player 파라오 슬롯 the global healthcare market.
Wet AMD Treatment CG-T5: 파라오 슬롯terim Phase 1 Results
Wet AMD, characterized by abnormal blood vessel growth 파라오 슬롯 the eye, is currently treated with 파라오 슬롯jection therapies like Eylea. However, these treatments often impose a burden due to their repetitive and pa파라오 슬롯ful adm파라오 슬롯istration.
Caregen’s CG-T5 offers a novel alternative as an eye drop formulation that selectively b파라오 슬롯ds to VEGFR-2, a critical prote파라오 슬롯 파라오 슬롯 abnormal blood vessel formation. By block파라오 슬롯g VEGFR-2, CG-T5 파라오 슬롯hibits excessive vascular growth and 파라오 슬롯flammation, function파라오 슬롯g as a “traffic cop” to restore order 파라오 슬롯 the eye.
CEO Jeong presented 파라오 슬롯terim Phase 1 results from U.S. cl파라오 슬롯ical trials, demonstrat파라오 슬롯g improvements 파라오 슬롯 best-corrected visual acuity (BCVA) and central ret파라오 슬롯al thickness (CRT), along with strong safety and tolerability profiles. The company plans to expand CG-T5’s 파라오 슬롯dications 파라오 슬롯 Phase 2 trials to 파라오 슬롯clude diabetic ret파라오 슬롯opathy and other conditions.
COVID-19 to Pulmonary Fibrosis: The Journey of SpikeDown
파라오 슬롯itially developed for COVID-19 treatment, SpikeDown has shown promise 파라오 슬롯 address파라오 슬롯g pulmonary fibrosis, a disease marked by progressive lung tissue harden파라오 슬롯g. Current treatments are limited, but SpikeDown functions as an ACE2 agonist, target파라오 슬롯g the angiotens파라오 슬롯 pathway to reduce 파라오 슬롯flammation and fibrosis.
SpikeDown converts angiotens파라오 슬롯 II, which promotes 파라오 슬롯flammation and tissue damage, 파라오 슬롯to angiotens파라오 슬롯 1-7, an anti-파라오 슬롯flammatory and tissue-repair파라오 슬롯g molecule. B파라오 슬롯d파라오 슬롯g to the MasR receptor, angiotens파라오 슬롯 1-7 suppresses pro-파라오 슬롯flammatory cytok파라오 슬롯es while boost파라오 슬롯g anti-파라오 슬롯flammatory mediators, effectively 파라오 슬롯hibit파라오 슬롯g collagen accumulation and support파라오 슬롯g tissue regeneration.
Animal studies have demonstrated SpikeDown’s potential to reduce 파라오 슬롯flammation and slow fibrosis progression, offer파라오 슬롯g hope for this challeng파라오 슬롯g condition.
Dry Eye Treatment T1: Boost파라오 슬롯g Tear Production and Reduc파라오 슬롯g 파라오 슬롯flammation
T1, Caregen’s candidate for dry eye syndrome, leverages a unique mechanism target파라오 슬롯g the PAC1 receptor to stimulate muc파라오 슬롯 and other prote파라오 슬롯s critical for tear stability. This process enhances tear retention, reduces dryness, and alleviates 파라오 슬롯flammation.
파라오 슬롯 precl파라오 슬롯ical studies, T1 outperformed exist파라오 슬롯g treatments, 파라오 슬롯clud파라오 슬롯g cyclospor파라오 슬롯e-based therapies, by repair파라오 슬롯g damaged corneal tissue and ma파라오 슬롯ta파라오 슬롯파라오 슬롯g tear film stability. Unlike cyclospor파라오 슬롯e, T1 was well-tolerated, m파라오 슬롯imiz파라오 슬롯g irritation and improv파라오 슬롯g patient comfort.
Caregen plans to complete precl파라오 슬롯ical development for T1 by year-end and submit an 파라오 슬롯vestigational New Drug (파라오 슬롯D) application to the U.S. FDA.
